Detalles de la búsqueda
1.
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.
Oncologist
; 28(3): 208-213, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36527702
2.
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Support Care Cancer
; 31(12): 654, 2023 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878086
3.
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
Oncologist
; 26(4): 325-331, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33289268
4.
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Future Oncol
; 17(23): 3027-3035, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878896
5.
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
J Natl Compr Canc Netw
; 18(6): 676-681, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502985
6.
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Support Care Cancer
; 28(2): 857-866, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31161436
7.
Prognostic value of endocervical sampling following loop excision of high grade intraepithelial neoplasia.
Gynecol Oncol
; 144(3): 547-552, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28081880
8.
Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction.
J Am Heart Assoc
; 12(10): e028820, 2023 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37158118
9.
A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort Study.
Front Med (Lausanne)
; 8: 679294, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34277658
10.
Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care.
JCO Oncol Pract
; 16(2): e132-e138, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31800352
11.
Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
J Med Econ
; 22(8): 840-847, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31094589
12.
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes.
Leuk Res
; 63: 10-14, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29078080
13.
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Leuk Res
; 60: 123-128, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28818807
14.
Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.
Leuk Lymphoma
; 58(11): 2649-2656, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28482722
15.
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
J Med Econ
; 19(4): 397-402, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26652728
16.
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Curr Med Res Opin
; 31(6): 1105-15, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25785551
17.
Total cost comparison in relapsed/refractory multiple myeloma.
J Med Econ
; 16(5): 614-22, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23281721
Resultados
1 -
17
de 17
1
Próxima >
>>